Fractyl Health, Inc. (NASDAQ:GUTS) CEO Sells $165,569.04 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan sold 90,972 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $1.82, for a total value of $165,569.04. Following the transaction, the chief executive officer now owns 491,329 shares in the company, valued at $894,218.78. This trade represents a 15.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Harith Rajagopalan also recently made the following trade(s):

• On Monday, November 11th, Harith Rajagopalan sold 96,517 shares of Fractyl Health stock. The shares were sold at an average price of $2.47, for a total value of $238,396.99.

Fractyl Health Price Performance

Fractyl Health stock opened at $1.64 on Thursday. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. Fractyl Health, Inc. has a 52-week low of $1.52 and a 52-week high of $11.55. The firm has a market cap of $78.88 million and a PE ratio of -0.13. The company’s 50 day moving average is $2.03 and its two-hundred day moving average is $2.47.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.02. The company had revenue of $0.01 million during the quarter. On average, research analysts expect that Fractyl Health, Inc. will post -1.66 EPS for the current fiscal year.

Hedge Funds Weigh In On Fractyl Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC acquired a new stake in Fractyl Health in the second quarter valued at approximately $61,000. SG Americas Securities LLC purchased a new stake in shares of Fractyl Health in the 3rd quarter valued at approximately $33,000. Beta Wealth Group Inc. acquired a new stake in shares of Fractyl Health in the 3rd quarter valued at $44,000. Massachusetts Financial Services Co. MA lifted its position in shares of Fractyl Health by 4.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock worth $2,646,000 after purchasing an additional 49,289 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Fractyl Health by 56.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock worth $204,000 after purchasing an additional 29,262 shares in the last quarter.

Analysts Set New Price Targets

Separately, Morgan Stanley dropped their target price on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a research report on Monday.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.